8-K: Passage Bio Reports Q2 2025 Results, Extends Cash Runway

Passage Bio announced its second quarter 2025 financial results, highlighting progress in its upliFT-D clinical trial for FTD-GRN and extending its cash runway into Q1 2027.

Summary

• Net loss for Q2 2025 was $9.4 million, or $2.96 per basic and diluted share, a significant improvement from a net loss of $16.0 million, or $5.09 per share, in Q2 2024.
• Cash, cash equivalents, and marketable securities totaled $57.6 million as of June 30, 2025, compared to $91.8 million as of June 30, 2024.
• The company projects its current cash, cash equivalents, and marketable securities will fund operations into the first quarter of 2027.
• Dosing of FTD-GRN Cohort 2 in the upliFT-D study was completed in July 2025, with Patient 9 treated with Dose 2 PBFT02.
• Updated interim data showed that PBFT02 continued to demonstrate robust, durable elevation in cerebrospinal fluid (CSF) progranulin (PGRN) levels and improvement in plasma neurofilament light chain (NfL), a disease progression biomarker.
• The amended upliFT-D study protocol was submitted to global trial sites and health authorities, allowing for enrollment of patients who are prodromal or have mild cognitive impairment.
• Research and Development (R&D) expenses decreased to $5.8 million for Q2 2025 from $10.4 million for Q2 2024.
• General and Administrative (G&A) expenses decreased to $4.5 million for Q2 2025 from $6.5 million for Q2 2024.

Sentiment

Score: 8

Explanation: The company reported a significantly reduced net loss and extended its cash runway, indicating improved financial management. Positive interim clinical data for PBFT02, including robust biomarker responses and progress in patient dosing, suggests promising therapeutic potential for FTD-GRN. While serious adverse events occurred, they were managed, and the overall clinical progress and financial outlook are encouraging for a clinical-stage genetic medicines company.

Positives

• Net loss significantly reduced to $9.4 million in Q2 2025 from $16.0 million in Q2 2024, indicating improved financial efficiency.
• Cash runway extended into Q1 2027, providing longer operational stability and reducing immediate capital raise concerns.
• Completed dosing of FTD-GRN Cohort 2 in the upliFT-D study, demonstrating continued progress in clinical development.
• PBFT02 showed robust and durable elevation in CSF PGRN levels through 18 months post-treatment in Dose 1 patients, with Dose 2 approaching the upper healthy adult range at one month.
• Plasma NfL, a key disease progression biomarker, showed a reduced annual rate of change in PBFT02-treated patients compared to natural history studies, suggesting potential disease modification.
• Successful submission of an amended upliFT-D study protocol, which broadens inclusion criteria to allow for enrollment of patients with prodromal or mild cognitive impairment.
• Significant year-over-year reductions in both R&D expenses ($5.8 million vs. $10.4 million) and G&A expenses ($4.5 million vs. $6.5 million), reflecting cost management.
• Achieved critical manufacturing milestones, including a functional potency assay and a high-productivity, suspension-based manufacturing process estimated to yield over 1,000 doses per lot.

Negatives

• Cash, cash equivalents, and marketable securities decreased to $57.6 million as of June 30, 2025, from $91.8 million as of June 30, 2024.
• Three out of eight patients experienced a total of four serious adverse events (SAEs), including asymptomatic venous sinus thrombosis and pulmonary embolism, although these responded to treatment.

Risks

• Ability to develop and obtain regulatory approval for product candidates.
• Timing and results of preclinical studies and clinical trials, which are inherently uncertain.
• Risks associated with clinical trials, including the ability to adequately manage clinical activities, unexpected concerns from additional data or analysis, and potential requirements for additional information or further studies by regulatory authorities, or delays/failures in approval.
• Occurrence of adverse safety events during clinical development.
• Risk that positive results in a preclinical study or early-stage clinical trial may not be replicated in subsequent or later-stage trials.
• Failure to protect and enforce intellectual property and other proprietary rights.
• Dependence on collaborators and other third parties for the development and manufacture of product candidates and other aspects of the business, which are outside of full control.
• Risks associated with current and potential delays, work stoppages, or supply chain disruptions.

Future Outlook

Passage Bio anticipates initiating enrollment of its third FTD-GRN and first FTD-C9orf72 patient cohorts following protocol amendment approval. The company expects to seek regulatory feedback on its suspension-based manufacturing process comparability in the second half of 2025, report updated interim safety and biomarker data from Dose 2 in the first half of 2026, and seek regulatory guidance on the registrational pathway for the FTD-GRN program in the first half of 2026. The company projects its current cash, cash equivalents, and marketable securities will fund operations into the first quarter of 2027.

Management Comments

• "We continue to be encouraged by the emerging data from our upliFT-D clinical trial, which underscore the potential of PBFT02 to offer differentiated therapy for the FTD-GRN patient community."
• "As we remain focused on execution, we are pleased to have completed dosing of Cohort 2 and submitted the amended protocol to global trial sites and health authorities as planned."
• "We look forward to initiating enrollment of our third FTD-GRN and first FTD-C9orf72 patient cohorts once the protocol amendment is approved at trial sites and remain on track to engage with health authorities in the first half of 2026 to seek guidance on the registrational pathway for the program in FTD-GRN."

Industry Context

Passage Bio operates in the highly specialized and competitive field of genetic medicines for neurodegenerative diseases, a sector characterized by significant unmet medical needs and high research and development costs. The company's focus on Frontotemporal Dementia (FTD-GRN and FTD-C9orf72) addresses conditions with no approved disease-modifying therapies, positioning PBFT02 as a potential first-in-class or best-in-class one-time gene therapy. The industry is seeing increasing interest in gene therapies and biomarker-driven drug development, with a trend towards leveraging natural history data as external controls for registrational studies, which Passage Bio plans to utilize.

Comparison to Industry Standards

• PBFT02 (Passage Bio's AAV1 gene therapy) achieved CSF PGRN levels of ~26 ng/mL (mean; n=4) at 12 months, with durability to 18 months. This compares favorably to Alector's anti-sortilin antibody (Phase 3), which showed ~4-5 ng/mL (n=9) at 12 months, and Lilly/Prevail's AAV9 gene therapy (Phase 1/2), which showed ~4-8 ng/mL (n=7 higher dose) at 12 months, with declining levels from 2 to 12 months.
• PBFT02's one-time intra-cisterna magna (ICM) administration contrasts with Alector's monthly intravenous (IV) administration, potentially offering a more convenient and less frequent treatment option for patients.
• The company's strategy to leverage natural history data (NHS) as external controls for registrational studies aligns with recent precedents in gene therapy (GTx) development, potentially streamlining the regulatory pathway and reducing the need for large, placebo-controlled trials.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical data, extended cash runway, and reduced burn rate. However, dilution risk remains given the clinical stage and potential future capital needs.
• Patients (FTD-GRN, FTD-C9orf72): Positive interim data for PBFT02 offers hope for a potential disease-modifying therapy where none currently exist. The amended protocol allows for broader patient enrollment.
• Employees: Continued employment and stability due to extended cash runway and ongoing clinical development.
• Regulatory Authorities: Engagement planned for feedback on manufacturing and registrational trial design, indicating adherence to regulatory processes.

Next Steps

• Initiate enrollment of Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) in the upliFT-D study, evaluating Dose 2 PBFT02, following protocol amendment approval.
• Seek regulatory feedback on suspension-based manufacturing process comparability in the second half of 2025.
• Report updated interim safety and biomarker data from Dose 2 in the first half of 2026.
• Seek regulatory feedback on registrational trial design in FTD-GRN in the first half of 2026.
• Advance the Huntington's disease preclinical program.

Key Dates

Recommendation

While the company demonstrated improved financial performance with a reduced net loss and extended cash runway, and reported encouraging interim clinical data for PBFT02, it remains a clinical-stage biotechnology company. The positive biomarker data is promising, but the occurrence of serious adverse events, even if managed, highlights inherent risks in drug development. The stock is likely to be volatile based on future clinical milestones and regulatory feedback. A 'hold' recommendation is appropriate given the positive developments balanced against the significant risks and the need for further clinical validation before a clear path to market is established.

Keywords

Passage Bio, PASG, Genetic Medicines, Neurodegenerative Diseases, FTD-GRN, Frontotemporal Dementia, PBFT02, Gene Therapy, Clinical Trial, UpliFT-D, Progranulin, PGRN, NfL, Biomarker, Financial Results, Biotechnology, Rare Disease